1. Voltas:

This consumer electronics company surged 10.8% on Monday after announcing Q1 results that beat estimates on all fronts. The company reported revenue growth of 45.8% YoY, reaching Rs 5,001.3 crore in Q1FY25, surpassing Trendlyne’s Forecaster estimate by 9%. Net profit rose 158.5% YoY to Rs 334.2 crore, beating the estimate by 35.9%.

If we look at the revenue mix, the company’s cooling products segment, which contributed more than 75% to its topline, saw volume growth of 67%. The heat waves drove demand up during the peak summer months, powering the segment’s revenue higher by 51% on a YoY basis. The electro-mechanical projects segment also saw revenue growth of 40% YoY to Rs 949 crore.

Voltas saw its market share fall to 18.7% in FY24 in air conditioners, down from 21.6% in FY23. Meanwhile, its major competitor Blue Star’s market share rose by 25 bps to 13.8%.and hopes to drive it higher by 100 bps every year. 

In its latest annual report, the company projects the overall AC market to grow at a CAGR of 10% in FY25-28. Managing Director and CEO, Pradeep Bakshi, said, “The company has begun the groundwork to set up a manufacturing plant in Tamil Nadu to cater the rising demand for ACs which has grown by 75% in the past few quarters.” He highlights that this facility will have a manufacturing capacity of 2 million cooling units and focus mainly on southern and western India.

BOB Capital Markets maintains its ‘Hold’ rating on Voltas as they are optimistic about future growth, considering the under penetration of ACs in India. They are also upbeat about the growth outlook of its home appliances brand ‘Voltas Beko’ which manufactures fridges, washing machines, etc. as it achieved 12% of sales from e-commerce channels in FY24.

2. Signatureglobal (India):

This realty company has risen 296.8% since its listing on September 23 of last year and has surged 8.9% in the past week following its results announcement on August 7. The company reported a net profit of Rs 6.8 crore in Q1FY25 compared to a net loss of Rs 7.2 crore in Q1FY24. Its operating revenue grew 141.5% YoY to Rs 400.6 crore, driven by a 148% YoY rise in sales in the real estate segment. It beat Forecaster revenue estimates by 92.6%.

Revenue growth was driven by the company’s pre-sales, which reached Rs 3,120 crore in Q1FY25, marking a remarkable growth of 255% YoY with a 63% CAGR in pre-sales over FY21-24. Pradeep Kumar Aggarwal, Chairman and Whole-Time Director, said, "In the first quarter itself, we have achieved 30% of our annual pre-sales target. We are planning to launch a few projects over the coming quarters, which are likely to boost our operational targets.” The growth is primarily due to the successful launch of Phase 1 of the group housing project 'TITANIUM SPR' in Sector 71, Gurgaon – the project has accounted for 87% of sales.

The company plans to increase its launches by four-fold YoY to 32 million sq. ft. (msf) worth Rs 16,000 crore in FY25 (from Rs 4,200 crore in FY24). Some of the existing projects in the pipeline for FY25 include premium projects in Gurgaon at Sector 71, Sector 84 and Sector 37D, worth Rs 8,700 crore, as well as mid-income projects with independent floors at Sohna, Haryana with gross development value (GDV) of approximately Rs 5,800 crore. Additionally, the company will launch industrial plot projects at Sohna and Manesar in Haryana, worth Rs 1,500 crore.

In Q4FY24 Signatureglobal had launched its first premium project, Deluxe-DXP at Sector 37D in Gurugram, which sold out in 48 hours. Its second high-priced project also received a strong response, with 85% of inventory sold at launch.

Motilal Oswal has initiated a ‘Buy’ rating with a target price of Rs 2,000. The brokerage believes that the strong pre-sales growth will lead to a rapid scale-up across key parameters, such as cash flows, revenue and profitability, enhancing the company’s execution capability and future growth potential. The firm expects the growth momentum to remain intact and estimates that Signatureglobal will deliver a 35% CAGR in bookings over FY25-27.

3. FSN E-Commerce (Nykaa): 

This internet retail company rose over 1% after its net profit surged 191.9% YoY to Rs 9.6 crore in Q1FY25. Revenue rose 22.8% YoY to Rs 1,746.1 crore during the quarter, driven by growth in the beauty & personal care (BPC) and fashion segments. The company’s revenue was in line with Trendlyne’s Forecaster estimates, but profit missed estimates by 43.5%. 

During the quarter, Nykaa’s GMV (gross merchandise value) grew 25% YoY, with the BPC segment’s (constituting over 76% of the total GMV) GMV rising 28%. Nykaa’s owned brands GMV grew 47% YoY in Q1. The fashion segment (which makes up 23% of the total GMV) saw its GMV increase by 15% YoY in a highly competitive space. Analysts noted that fashion GMV growth was slower compared to 27% in Q4FY24, due to a drop in store visits, and slower demand amid fewer wedding dates during the quarter. Nykaa provided discounts across its beauty and fashion categories due to the lack of festivities, but expects discounts to moderate in Q3 and Q4 as demand picks up in the festive season.

Meanwhile, Nykaa continued to expand its retail network, with stores reaching the 200 mark. During the quarter, the company announced the acquisition of an additional 39% stake in Dot & Key Wellness for Rs 265.3 crore. With this, company's stake will increase from 51% to 90%. Earlier in March the e-commerce company entered the GCC (Gulf Cooperation Council) Beauty space, under the brand Nysaa. GCC Beauty is estimated to be a $30 billion market and the company expects this to be a significant growth driver in the future.

Nykaa increased its warehouse count to 44 in Q1, with an aim to improve its delivery timelines. Falguni Nayar said, “Given the investments we have made in the space, our key objective is to improve consumer experiences by getting the product into the consumer’s hands faster. We aim to deliver 70–80% of orders placed in major cities and 50% of other cities, on the same day or the next day by September”.

ICICI Securities maintains its ‘Add’ rating with a target price of Rs 210. The brokerage remains cautious on the company and believes success in the fashion business can be difficult given the intense competition in the category. 

4. Aurobindo Pharma: 

This pharmaceuticals company rose by 4.1% in three sessions after posting its Q1FY25 results on Saturday. Its revenue increased by 10.5% YoY to Rs 7,567 crore, in line with Forecaster estimates, driven by improvements in the US, Europe, and in rest of the world (ROW) formulations, as well as a rise in the active pharmaceutical ingredient segment. 

The company’s stock price rose by 4.5% on August 7 after it received final approval from the US FDA to manufacture and market Estradiol Vaginal Inserts. The drug is a generic equivalent of Novo Nordisk’s VAGIFEM, and has an estimated market size of $268 million. However, it pared its gains on Friday and fell 2% after the US FDA issued a warning letter for its Eugia II formulations manufacturing plant.

Aurobindo’s net profit grew by 61.5% YoY to Rs 919.2 crore, backed by reduced raw material costs. However, net profit still missed Forecaster estimates by 3.1%. The US formulations segment (which contributes to 47% of total revenue) witnessed just 8% revenue growth YoY. Growth was helped by improvements in specialty and injectables. 

Growth was muted and in single digits due to the remedial actions taken by the company after the US FDA issued an official action indicated (OAI) status on its Eugia III plant. The rest of the world (ROW) formulations experienced a 49.2% YoY rise in revenue during the quarter, led by new product launches. 

The company has been rapped on the knuckles multiple times by the FDA this year, and received multiple Form 483s or its Eugia plant in India since December 2023. This has resulted in a hit of $30-40 million in its revenue in Q4FY24 and Q1FY25, combined with a remediation cost of $8-9 million for the plant. These consistent issues have led to the company posting a 3-year revenue CAGR of 5.5%, which is lower than its competitors like Cipla (10.9%), Dr Reddy’s Laboratories (14.3%) and Sun Pharmaceutical Industries (13.2%). As a result, the company has developed the Vizag plant as a back-up and expects US FDA approval by the end of FY25. Puvvala Yugandhar, CEO of Eugia, expects the plant to be running at full capacity from Q2FY25 onwards.

Speaking on the company’s results, its Vice-Chairman and MD, K Nithyananda Reddy, says, “Our EBITDA margin remained at 21.4% and is in line with expectations. EBITDA margins are supported by stable raw material prices. We are confident in our ability to achieve our EBITDA growth target of 21-22% for FY25. We also expect the current pricing scenario in the US market to continue.” 

Post results, Axis Direct maintains its ‘Buy’ call on the company with a higher target price of Rs 1,612 per share. This indicates a potential upside of 7.3%. The brokerage remains confident about the stock due to its new launches in the US formulations and planned entry into biosimilars, peptides, and contract development & manufacturing organizations (CDMO) services. It expects the company’s revenue to grow at a CAGR of 5.7% over FY25-26.

5. Oil India:

This oil exploration and production company rose by 10.6% over the past week after the Ministry of Petroleum and Natural Gas approved a 20% premium on gas prices from new wells. Oil India plans to grow its gas output by 50% over FY25-26, building gas production infrastructure to increase domestic production.

The company’s net profit rose 32.2% YoY to Rs 1,885.8 crore, helped by inventory destocking. Revenue grew 30.9% YoY to Rs 9,350 crore in Q1FY25, beating Trendlyne’s Forecaster estimates by 70%. The Gross Refining Margin (GRM) of Numaligarh Refinery (NRL) stood at $6.4 per barrel in Q1FY25, compared to a negative margin of $15.6 per barrel in Q1FY24. 

Analysts predict that the GRM across the industry will decline to $6-8 per barrel in FY25, down from an average of $10-12 per barrel in FY24 – a narrowing discount on Russian crude and a decrease in the profit margin from selling refined products are impacting GRMs.

The company’s NRL expansion project, with a total cost of Rs 28,000 crore, has achieved 65% progress and is expected to be completed by December 2025. CFO Rupam Baura said “Once the new capacity is installed, we expect it to operate at around 50-60% in the first year, gradually ramping up to 90% by the second year. This expansion will increase the refinery’s capacity from 3 MMTPA to 9 MMTPA.” The firm plans to build a gas pipeline to connect the stranded North Brahmaputra fields which has a capacity of 3 bcm, equivalent to FY24 gas production.

Post results, Prabhudas Lilladher has upgraded the stock to ‘Buy’ with a raised target price of Rs 766. This indicates a potential upside of 13%. It remains positive about the NRL expansion, expecting it to boost gas production. Prabhudas Lilladher predicts that Oil India will see volume CAGRs of 8% for oil and 16% for gas over FY25-26.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.